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Background: Germline mutations in the BRCA1 and BRCA2 genes account for 20–25 % of inherited breast cancers
and about 10 % of all breast cancer cases. Detection of BRCA mutation carriers can lead to therapeutic
interventions such as mastectomy, oophorectomy, hormonal prevention therapy, improved screening, and targeted
therapies such as PARP-inhibition. We estimate that African Americans and Hispanics are 4–5 times less likely to
receive BRCA screening, despite having similar mutation frequencies as non-Jewish Caucasians, who have higher
breast cancer mortality. To begin addressing this health disparity, we initiated a nationwide trial of BRCA testing of
Latin American women with breast cancer. Patients were recruited through community organizations, clinics, public
events, and by mail and Internet. Subjects completed the consent process and questionnaire, and provided a saliva
sample by mail or in person. DNA from 120 subjects was used to sequence the entirety of BRCA1 and BRCA2
coding regions and splice sites, and validate pathogenic mutations, with a total material cost of $85/subject.
Subjects ranged in age from 23 to 81 years (mean age, 51 years), 6 % had bilateral disease, 57 % were ER/PR+, 23 %
HER2+, and 17 % had triple-negative disease.
Results: A total of seven different predicted deleterious mutations were identified, one newly described and the
rest rare. In addition, four variants of unknown effect were found.
Conclusions: Application of this strategy on a larger scale could lead to improved cancer care of minority and
underserved populations.
Keywords: Breast cancer, Hispanic populations, Genetic testing, Underserved populations, Health disparityBackground
Mutations in the BRCA1 and BRCA2 genes result in pre-
disposition to breast and ovarian cancers [1, 2]. In addition,
there is increasing evidence that BRCA mutations confer
risk for cancers of the prostate, pancreas, stomach and skin
[3–5]; there is also suggestive evidence for their involve-
ment in esophageal and gastric cancers [6]. In Caucasian
and Asian ethnicities, BRCA mutations are associated with
basal-type and/or –triple-negative disease (in which the* Correspondence: deanm@mail.nih.gov
1Laboratory of Experimental Immunology, National Cancer Institute,
Frederick, MD 21702, USA
Full list of author information is available at the end of the article
© 2015 Dean et al. Open Access This article
International License (http://creativecommo
reproduction in any medium, provided you
link to the Creative Commons license, and
Dedication waiver (http://creativecommons
article, unless otherwise stated.estrogen, progesterone, and HER2 receptors are absent
from the tumor); however, the nature of this relationship in
other ethnicities is understudied [7–10].
The identification of BRCA1/2 carriers is a critical com-
ponent of breast and ovarian cancer prevention as there are
multiple screening, surgical, and chemoprevention strat-
egies that can be employed. Magnetic resonance imaging
(MRI) screening is effective in detecting early cancers in
BRCA1/2 carriers; mastectomy and oophorectomy can re-
duce ovarian cancers; and estrogen inhibition can reduce
both type of malignancy [11]. However, relatively few mi-
norities have participated in these prevention studies.is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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lower incidence of breast cancer, they have a higher mortal-
ity. Triple-negative breast cancer is more common in
African Americans and Hispanic women, accounting, in
part, for this health disparity [12–16]. A study of over
45,000 women referred for BRCA1 and BRCA2 mutation
screening from 2006 to 2008, found that 13–16 % of
African Americans, Native Americans and Hispanics pos-
sess disease-causing mutations and a high rate of variants
of unknown significance [17]. An independent study of 389
African Americans and 425 Hispanic women with incom-
plete gene sequencing, found that 8–10 % of high-risk sub-
jects have a BRCA1 or BRCA2 gene mutation, and a small
Puerto Rican study reported a 52 % mutation rate [18, 19].
Common recurrent mutations, including large dele-
tions in BRCA1 and BRCA2, exist in Hispanic/Latin
American communities, which accounted for 35–45 %
of the mutation carriers [17–20].
The BRCA1 and BRCA2 proteins play a role in the re-
pair of double-stranded breaks in DNA. A synthetic le-
thal strategy for cancer therapy has been developed
using DNA damaging chemotherapy agents to cause
single-stranded breaks, combined with poly-ADP ribose
polymerase (PARP) inhibitors, to inhibit single-stranded
DNA repair. This approach may be particularly effective
in BRCA mutation carriers, as the tumor will be unable
to repair the double-stranded breaks [21, 22]. Clinical
trials of PARP inhibitors demonstrate partial response
or stable disease in breast, ovarian and prostate cancer
subjects [23–27].
Mutations in BRCA1 and BRCA2 have been detected
with a variety of techniques including multiple mutation
scanning methods and Sanger sequencing (reviewed in
[28]). Next-generation sequencing (NGS) has the benefit
of high-throughput, automated sequence analysis, and
single strand reads. DNA capture, droplet PCR and
multiplex PCR methods of template preparation, and se-
quencing on 454, Illumina and Ion Torrent platforms
have all been employed [29–32]. A clinical diagnostic la-
boratory validation of the Ion Torrent platform demon-
strated an absence of false negatives and a 10 % false
positive rate [33]. With the availability of a three-tube
multiplex for the complete BRCA1 and BRCA2 genes
we sought to apply this approach to a cohort of His-
panic/Latin American breast cancer patients.
Data description
The data involve variants in the coding and flanking intron
sequences of the human BRCA1 and BRCA2 genes in
Hispanic subjects with breast cancer. The sequence was
identified through amplification, library preparation and
semi-conductor sequencing on an Ion Torrent Personal
Genome Machine (PGM) Sequencer (Thermo Fisher
Scientific) to an average (for all samples and amplicons of2293-307X) coverage in runs with 92 samples/chip and
466X with 46 samples/chip. Excluding samples giving fewer
than 20,000 total reads, 1 amplicon of BRCA1 was below
100x average reads (beginning of exon 2, containing 32 bp
of the 5’UTR and 1 splice acceptor site); and 4 amplicons
of BRCA2 had <100× average, covering 261 bp of coding
region and 5 splice sites. Therefore, the coverage of the
coding regions is 100 % for BRCA1 and 98 % for BRCA2.
The data consist of raw sequence reads mapped to the
human genome, and the resulting BAM files. These files
were used to predict sequence variants using the Torrent
Suite Variant Caller (TSVC) and a modified Genome Ana-
lysis Tool Kit (GATK) variant caller, optimized for PGM
data. For SNPs, the two variant callers (VCs) give virtually
identical results, each calling one intronic SNP the other
missed (both present on manual inspection). GATK is
known to be ineffective at calling indels on the Ion Torrent
platform. Parameter files for TSVC are given, as well as the
raw and annotated variant files. Variants were manually ex-
amined in the Integrated Genome Viewer (IGV) and se-
lected screen shots are provided. Rare variants were
annotated to be Deleterious, Probably Benign, or Benign
through inspection of appropriate databases (see Methods).
Deleterious variants were validated by Sanger sequencing
and displayed in Mutation Surveyor (SoftGenetics). Infor-
mation on variants has been deposited in the LOVD ID
#0000058963 [34].
Clinical data consists of information on the pathology
of the tumor extracted from pathology reports, and re-
sults of a questionnaire administered by study personnel.
Data are managed in a FileMaker relational database,
and information on mutation carriers was double
checked for accuracy. The composite information is dis-
played in Table 2, as well as the age-of-onset, pathology,
hormone receptor status, and family history of cancer
status of those subjects with mutations.
Analyses
Study design and patient population
To estimate the participation rate of minorities in BRCA1
and BRCA2 testing we used data from Hall et al. [35], on
64,717 non-Ashkenazi women receiving testing at Myriad
Genetic Laboratories between the years 2006 and 2008,
in order to calculate participation. Women of Western
European descent made up 78 % of the subjects receiving
testing during this time period. Latin American and
African American women each made up only 4 % of the
samples, despite representing 16 and 13 % of the US
population, respectively. This represents 18.4 European
Americans screened/100,000 as compared to 3.8/100,000
for Hispanics and 4.7/100,000 for African Americans
(Table 1). Therefore, Hispanic and African American
women are 4–5 times less likely to receive BRCA genetic
testing than Western European women (Fig. 1). Economic
Table 1 BRCA screening by ethnicity
West Eur Cent Eur Latin Am African Asian Nat Am Mid East All
BRCA1 2501 336 185 180 75 44 30 3351
BRCA2 1899 214 105 100 75 35 16 2444
Total mutant 4400 550 290 280 150 79 46 5795
Subjects 36235 4066 1936 1767 1183 597 492 46276
% Mutation 12 % 14 % 15 % 16 % 13 % 13 % 9 % 13 %
Ratio BRCA1/2 1.32 1.57 1.76 1.80 1.00 1.26 1.88 1.37
% Sample 78 % 9 % 4 % 4 % 3 % 1 % 1 %
US pop (1000s) 196817 50477 37686 14465 2247
Screened/100,000 18.4 3.84 4.69 8.18
Ratio West Eur/minority 4.80 3.93 2.25
Data from Hall et al. [17] on BRCA screening and mutations identified by ethnic group were used to calculate the ratio of BRCA1/BRCA2 mutations (ratio BRCA1/2),
and the percentage of the total sample represented by that ethnicity (% sample). The size of selected ethnic groups according to the US Census in thousands (US
Pop (1000s)) divided by the number of subjects yields the number screened per 100,000 (Screened/100,000). The ratio of Western Europeans (West Eur) screened
to Latin Americans (Latin Am), African Americans (African), and Asian American (Asians) was calculated by dividing Screened/100,000 for West Eur (18.4) by the
corresponding figure of the minority population (Ratio West Eur/minority). Including the Central European (Cent Eur) women in with the West Eur women raises
the minority ratios slightly (not shown)
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surance coverage are likely to play roles in this deficit.
We designed a clinical trial to address some of these
issues, with recruitment of Latin American women
through community organizations, clinics with large
Hispanic populations, public events, and the Internet.
Study materials were available in Spanish and English,
and the patients were protected by a certificate of confi-
dentiality [36]. We recruited a total of 135 subjects from
10 different states, and had an 88 % success rate in
terms of completion and collection of consent forms,
questionnaires, saliva samples, and pathology reports.
The use of a saliva collection device that can be sent by
regular mail allowed the materials cost of collection,
shipping, and DNA extraction to be less than US$25.Fig. 1 BRCA screening by ethnicity. The numbers of Western European (
(African) women who received BRCA screening per 100,000 population
(see Table 1 for details)
3The subjects had an age range at diagnosis of 23–81
years (mean 50.6 years); 60 % had a household income
below $25,000; and 81 % were educated to high school
level or less (Table 2). A total of 85 % of the subjects
had invasive ductal carcinoma, 6 % bilateral disease, and
57 % ER/PR+, 23 % HER2+, and 17 % triple-negative
disease. A family history of either a first or second-
degree relative with breast cancer was identified in 35 %
of cases.
DNA sequencing of BRCA1 and BRCA2
An aliquot of each DNA sample was stripped of all
identifiers in order to comply with the requirements of
the protocol. A previously validated panel of primers
(Ion AmpliSeg BRCA1 and BRCA2 Community Panel)West Eur) women, Latin American (Latin Am), and African American
between 2006 and 2008, covered by Hall et al. [17] is displayed
Table 2 Demographics of subjects
All BRCA1 or 2 mutation
Yes No
Patients 120 12 (10 %) 108 (90 %)
Triple-negative 20 (17 %) 6 (50 %) 14 (13 %)*
ER&PR positive 67 (57 %) 3 (25 %) 64 (61 %)*
HER2 positive 27 (23 %) 0 27 (26 %)*
Histology
Invasive Ductal Carcinoma (IDC) 98 (85 %) 11 (92 %) 87 (82 %)
Ductal Carcinoma In Situ (DCIS) 11 (9 %) 0 11 (10 %)
Invasive Lobular Carcinoma (ILC) 4 (3 %) 0 4 (4 %)
Other/rare 4 (3 %) 1 (8 %) 3 (3 %)
Age at diagnosis 50.6 ± 11.6 43.7 ± 11.8 51.4 ± 11.3*
Age at first menses 12.8 ± 1.6 12.3 ± 1.4 12.8 ± 1.6
Education
High school diploma or less 95 (81 %) 8 (66 %) 87 (82 %)
Beyond high school 23 (19 %) 4 (34 %) 19 (18 %)
Household Income
< $25,000 61 (60 %) 1 (10 %) 60 (65 %)
> $25,000 41 (40 %) 9 (90 %) 32 (35 %)
Family history of BRCA 42 (35 %) 6 (50 %) 36 (34 %)
*Significantly different, P < 0.05
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(24,143 bp) with an average coverage of 313–466X and
100 % coverage (>100X average) of the BRCA1 and
98 % of the BRCA2 coding sequence. Variants were
predicted using the Torrent Variant Caller; all pre-
dicted frameshift and premature stop codon alleles,
and all other variants represented at less than 5 % in
the 1000genomes database [37] and with quality scores
greater than 40 were manually examined in IGV, and
predicted deleterious variants were further confirmed
by manual Sanger sequencing. A total of seven clearly
deleterious alleles were identified, including a newly
described allele: a single nucleotide deletion in BRCA1
(6005delT, c.5777delT). The other six alleles were unique
and, except for 189del11 in BRCA1 and E1308X in BRCA2,
all represent mutations uncommonly seen in these genes
(Fig. 2, Table 3). Six of the seven mutations are frameshift
or termination codons. The one missense variant is a com-
pound allele C1787S and G1788D. These alleles have been
reported five times in BIC [38] and have been proposed to
be in cis on the same allele. NGS confirms this (Fig. 2).
Several rare missense alleles were found, but by using
data in BIC and ClinVar, all but four could be excluded as:
known; likely non-pathogenic variants; or those found in a
sample with an existing mutation (Table 3). Two of these
variants of unknown significance (VUS) are not present in
BIC (BRCA1 E577Q and BRCA2 F266L). To further inter-
rogate the variants of unknown significance, the Align4GVGD site for evolutionary conservation [39] and LOVD
[34] databases were examined. One of the VUS (BRCA1
T826K) is listed as neutral in LOVD and the other three
(F266L, E577Q and D1781N) are ranked as C0 (not con-
served) in GVGD. It has been shown that an alignment of
only primate sequences provides a potentially more appro-
priate model for human genetic variants [40]. Therefore, an
alignment of all available primate BRCA1 and BRCA2
amino acid sequences was generated and the conservation
of the residues determined. This analysis ranked all but one
of the VUS (E577Q) as likely benign or benign (Table 3).
E577Q is found in a patient with triple-negative disease and
one second-degree relative with breast cancer.
Women with deleterious mutations were younger
(43 versus 51 years of age, P = 0.029). Two of the seven
patients with deleterious mutations had triple-negative
disease (29 %); this is not significantly different from
those patients without identified mutations. Only two of
the patients with identified mutations had a family history
of breast cancer, with one second-degree relative in each
case. This frequency of a family history, 29 %, was not sig-
nificantly different to that of the cohort as a whole.
Testing of a highly accurate sequencing enzyme
Most sequencing technologies have a higher error rate
at mononucleotide stretches of DNA. We previously docu-
mented this in a comparison of Ion Torrent, Illumina and
Complete Genomics NGS machines [41]. While the latest
version of TVC has eliminated most apparent 1 bp dele-
tion artifacts, we identified a substantial number of appar-
ent erroneous coding 1 bp insertions and deletions in
mononucleotide regions, especially poly-A or poly-T
repeats (Table 4).
A recently developed enzyme, Ion Hi-Q Sequencing
Chemistry, has been designed by Life Technologies for
higher accuracy with respect to insertions and deletions
(indels) and homopolymers (Ion Hi-Q Sequencing Chem-
istry Technology Access Program Information). We
sequenced the same library of 91 DNA samples using both
the standard and the Hi-Q enzyme, and analyzed the re-
sults according to the manufacturer’s instructions. With
the Hi-Q enzyme the number of false positives was lower
especially for 1 bp deletion alleles (Table 4, Fig. 3). The
use of Hi-Q could greatly streamline variant prediction by
reducing the number of variants requiring manual review.
Discussion
Rates of mortality, triple-negative disease, and BRCA1 and
BRCA2 mutational and allelic diversity are all higher in
African American and Hispanic populations. Although
these populations could benefit significantly from genetic
testing and screening, the combination of lower average
income; lower insurance coverage; reduced knowledge of
the benefits of testing; and mistrust of medical and
Fig. 2 Selected BRCA2 mutations. The Ion Torrent data displayed in IGV [51] is shown for the newly described 6005delT mutation in the left
panel, a. The display shows individual forward (F) sequence reads in red and reverse (R) reads in blue. The 6005delT mutation can be seen as a
gap in the sequence (arrow) in approximately half of the F and R reads – this is consistent with a heterozygous mutation. Sanger sequencing
(not shown) confirmed this mutation. b. Both the Ion Torrent (above) and Sanger sequence (displayed in Mutation Explorer, SoftGenetics, below)
for the C1787S and G1788D mutations are displayed in the right panel. The co-occurrence of the C1787S and G1788D variants on the same allele
can be clearly seen in the Ion Torrent reads, whereas phase cannot be determined from the Sanger traces. Note: BRCA1 is in reverse orientation
in the genome, and so IGV display is of the reverse complement
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ticipation [42–44]. From 64,717 women in the Myriad
database, this under-participation is 3.9–4.8 times lower
in these two populations, which together account for 29 %
of the US population [35]. A similarly low rate of partici-
pation from the first 10,000 women tested at Myriad was
noted by Forman and Hall [43].
To begin to address these issues in Hispanic popula-
tions, we designed a study with a number of potential
advantages:5 a fully de-linked sample not requiring extensive
counseling regarding BRCA testing;
 collection of saliva that can be completed in the
home, community clinics or public events;
 bilingual study materials; and
 full protection of confidentiality.
Our recruitment success was very modest from online
publicity (Facebook, clinicaltrials.gov), and few minority
patients participate in public fund-raising events, such
Table 3 Classification of mutations and non-synonymous variants
Classification Gene Allele IDS HGVS cDNA BIC ClinVar GVGD
prediction




Pathogenic BRCA1 188insAG rs80357914 c.69_70insAG 2X IDC&LC No No No 35
Pathogenic BRCA1 189del11 rs80359877 c.70_80del 11X IDC Yes No No 29
Pathogenic BRCA1 5210delTG rs80357710 c.5091_5092delTG 2X IDC Yes No 1-2nd 32
Pathogenic BRCA1 G1788D rs80357069 c.5363G>A 5X IDC No No No 38
* BRCA1 C1787S rs80357065 c.5359T>A 5X
Pathogenic BRCA2 Q742X rs80358494 c.2224C>T 2X IDC No 1-2nd 39
Pathogenic BRCA2 E1308X rs80358638 c.3922G>T 15X IDC No No No 41
Pathogenic BRCA2 6005delT c.5778delT Not in
BIC
IDC No No No 35




Class C0 IDC Yes No 1-2nd 49
VUS BRCA2 F266L rs587782433 c.796T>C Not in
BIC
1 VUS Class C0 IDC Yes No 1-1st 61
VUS BRCA2 D1781N rs183478654 c.5341G>A Not in
BIC
1 VUS Class C0 IDC&LC
Likely Benign BRCA1 L1844R rs80357323 c.5531T>G 3X 2LB Class C0
Likely Benign/
Benign
BRCA1 R504H rs56272539 c.1511G>A 19X 2LB_1B Class C0
Likely Benign/
Benign
BRCA1 T826K rs28897683 c.2477C>A 38X 1 LB
_3B










BRCA1 I1275V rs80357280 c.3823A>G 13X 1
LB_2B
Class C0 IDC Yes No No
All rare non-synonymous and coding region insertions and deletions were classified from a combined analysis of data from ClinVar, the Breast Cancer Information
Core (BIC), and conservation. The subject’s pathology classification (Path), triple-negative status (TN), bilateral disease status (bilat), family history (Hist), and age of
diagnosis (Age) are shown
IDC intraductal carcinoma, LC lobular carcinoma, 1st first degree relative, 2nd second degree relative
aC1787S/G1788D occur in cis in the same subject
bThis patient also carries the BRCA1 189del11 mutation
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community groups such as Nueva Vida (Baltimore,
Richmond) and the Latino Community Development
Agency (Oklahoma City) were successful in recruiting
a number of Hispanic women of diverse backgrounds.
The remainder of the population samples were col-
lected at the Texas Tech University Health Science
Hospitals in Lubbock and El Paso, Texas. By sending
and receiving saliva kits through the US mail we were
able to keep the cost of the collection/shipping and
DNA preparation materials to under $20 per subject.
Targeted sequencing, performed in batch sizes of 90
samples, has a materials cost of approximately $50,
making the total reagent cost under $100, including
Sanger validation but excluding labor. This is an im-
portant factor if sample sizes in the order of thousands
of subjects are to be eventually attained.
We did identify amplicons in BRCA2 that performed
poorly in most samples, having <100X average coverage,
comprising 261 bp of coding region and 4 splice sites,
and 1 splice site of BRCA1 poorly covered. The initial6run of 92 samples had three that underperformed and
required repetition (3 %); however, these samples per-
formed well on a second run. Our second run of 46
samples allowed the average coverage to increase from
313–361X to 466X. Running 46 samples on a single chip
would raise the cost/sample by $5, and may be advisable
for clinical testing.
The BRCA1 gene contains multiple mononucleotide re-
peats, for which it is challenging to accurately detect 1 bp
indels; these regions are the most problematic to detect
for all current methods [36, 40, 41]. Early versions of the
TVC demonstrated relatively higher error rates on homo-
polymer sequences [40, 41]. This performance has im-
proved with subsequent version of TVC and three studies
demonstrate that 70-130X coverage across homopolymer
regions is sufficient to get accurate mutation calls in the
BRCA1 and BRCA2 genes (Table 5, Additional file 1)
[42, 43]. Using the 70X standard of Dacheva et al., besides
the poor performing exons mentioned above, there are
only 2 A5 homopolymer repeats in coding regions
(BRCA2, exon 12, 65X average coverage) that are below
Fig. 3 Screenshots of selected variants. a, A region with multiple homopolymers in BRCA1 is shown, sequenced by the two enzyme
formulations. b. A missense variant (benign) that was not called with the standard enzyme, but was by Hi-Q
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here that the Hi-Q formulation and current TVC analysis
settings result in a substantial reduction in 1 bp indel calls,
especially in false positive mononucleotide regions. Man-
ual analysis of BAM files in IGV allows most of these vari-
ants to be excluded from consideration, although the
difference in background between the two enzymes visible
in IGV displays are not dramatic. The addition of overlap-
ping amplicons in the most difficult regions could im-
prove this result. Although we chose an amplicon-based
method on Ion Torrent, the samples could also be run on
multiple platforms or used in a capture-based method
[29]. Color Genomics (https://getcolor.com/) now offers a
clinical test of 19 breast cancer related genes for $249.
While this initial phase of the project was designed to
maximize participation and diversity at a modest cost, it
has the disadvantage that subjects with mutations could
not be retrospectively identified in order to benefit from
the testing. A second phase, in which identifiers will be
retained and patients counseled about testing, will now be
initiated. We expect recruitment to increase as several in-
dividuals and groups declined to participate in the7unlinked arm of the study. Population growth; advance-
ment in age of the US Hispanic populations; and large
family size make it imperative that innovative means be
employed to increase participation in clinical and genetic
studies. The increasingly recognized involvement of germ-
line mutations in BRCA1 and BRCA2 in diverse cancers,
as well as the active design of targeted therapies, further
adds to the need to recruit minority subjects.
To date there have been no large nationwide surveys
of Latin American with breast cancer. In the report by
Hall et al., only the identities of mutations reaching 4 %
or greater were made available [35]. The Clinical Cancer
Genetics Community Research Network collected sam-
ples and data from 746 patients from 14 clinics concen-
trated in Southwestern USA, and individual data from
centers in Texas, California, and Puerto Rico [46]. Our
study adds to the diversity of Hispanic BRCA muta-
tions, and – interestingly – we did not find the most
common allele in all mainland US Hispanic studies to
date, the BRCA1 185delAG mutation. Of the six muta-
tions we identified, only one, BRCA2 E1308X, has been
reported in multiple studies. A much larger study,
Table 4 Hi-Q vs. Standard enzyme variant call comparison
Sample CHR Location IDS REF VAR Standard QUAL HiQ QUAL Context
Rare coding indels
DL0099844 chr13 32906535 T Artifact 10.3 No call T5
DL0099806 chr13 32906547 T Artifact 93.64 No call T5
DL0099818 chr13 32906547 T No call Artifact 13
DL0099791 chr13 32906565 A Artifact 622.5 No call A6
DL0099802 chr13 32906565 A Artifact 737.8 No call
DL0099818 chr13 32906565 A Artifact 160.3 No call
DL0099828 chr13 32906565 A Artifact 793.8 No call
DL0099833 chr13 32906565 A Artifact 383.3 No call
DL0099840 chr13 32906565 A Artefact 744.6 No call
DL0099874 chr13 32906565 A Artefact 458.6 No call
DL0099818 chr13 32906576 A Artefact 158.9 No call A5
DL0099879 chr13 32906576 A Artefact 161.1 Artifact 293.2
DL0099824 chr13 32906576 A No call Artifact 373.7
DL0099842 chr13 32906576 A No call Artifact 212.6
DL0099846 chr13 32906576 A No call Artifact 325.6
DL0099851 chr13 32906576 A No call Artifact 288.0
DL0099832 chr13 32906602 A Artifact 101.0 No call A7
DL0099854 chr13 32906602 A Artifact 80.27 No call
DL0099812 chr13 32906609 AAT Artifact 11.8 No call A7T4
DL0099867 chr13 32906609 AT Artifact 19.39 No call
DL0099873 chr13 32906609 AAT Artifact 20.66 No call
DL0099879 chr13 32906609 AT Artifact 45.22 No call
DL0099806 chr13 32906647 A Artifact 32.02 No call A5
DL0099841 chr13 32906647 A Artifact 33.75 No call
DL0099808 chr13 32913668 A Artifact 11.78 No call A4
DL0099791 chr13 32914270 T Valid 627 Valid 583.7 agTg
DL0099847 chr13 32929161 A Artifact 13.91 No call A6
DL0099795 chr13 32929287 A Artifact 22.35 No call A4
DL0099802 chr13 32929287 A Artifact 12.56 No call
DL0099804 chr13 32929287 A Artifact 14.27 No call
DL0099816 chr13 32929287 A Artifact 16.41 No call
DL0099821 chr13 32929287 A Artifact 10.65 No call
DL0099831 chr13 32929287 A Artifact 10.4 No call
DL0099839 chr13 32929287 A Artifact 15.97 No call
DL0099844 chr13 32929287 A Artifact 16.08 No call
DL0099880 chr13 32929287 A Artifact 20.42 No call
DL0099874 chr17 41215952 rs80357710 CA Valid 893 Valid 794.1 CA4
DL0099847 chr17 41256244 T Artifact 13.14 No call T4
DL0099801 chr17 41276044 rs80359877 CAGATGGGACA Valid 856 Valid 611.1
DL0099855 chr17 41276044 CT Valid 483 Valid 608.1
Rare SNVs
DL0099801 chr13 32906446 rs28897705 T G Valid 348 Valid 469.2
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Table 4 Hi-Q vs. Standard enzyme variant call comparison (Continued)
DL0099870 chr13 32906571 rs55939572 A C No call Artifact 41.04
DL0099797 chr13 32912414 rs80358638 G T Valid 316 Valid 343.4
DL0099879 chr13 32912553 cosmic:69844,esp,rs80358656 C T Valid 343 Valid 405.2
DL0099858 chr13 32972695 rs80358387 A G Valid 520.1 Valid 608.6
DL0099877 chr17 41197756 rs80357323 A C Valid 522.5 Valid 675.3
DL0099816 chr17 41201181 rs80357069 C T Valid 512 Valid 799.2
DL0099816 chr17 41201185 rs80357065 A T Valid 519 Valid 805.8
DL0099879 chr17 41222976 rs80356968 A G Valid 560.3 Valid 495.7
DL0099858 chr17 41243948 rs56214134 C A Valid 758.5 Valid 698.1
DL0099836 chr17 41245071 rs28897683 G T Valid 325.6 Valid 248.3
DL0099801 chr17 41246037 rs56272539 C T Valid 835.4 Valid 998.0
DL0099838 chr17 41267755 T A Valid 731.1 Valid 910.6
A set of 91 samples were amplified and the resulting library run on either the standard sequencing enzyme or Hi-Q. Variants were called by TVC4.0 with recommended
settings optimized for Hi-Q enzyme (see Methods). Lines in bold were manually validated
REF reference base, VAR variant base. QUAL quality score of variant
Dean et al. GigaScience  (2015) 4:50 incorporating all the regional and ethnic diversities of
Hispanic populations, will have to be carried out to
fully understand mutational diversity, and to aid in the
classification of VUS.
Clearly, a comprehensive characterization of our sam-
ples will require copy number analysis to identify large
insertion/deletion mutations. Recurrent large deletions
in BRCA1 have been found in both Mexican and Puerto
Rican breast cancer patients [19, 20]. Rare germline
mutations in other genes have been identified in familial
breast cancer, and our samples could be used to scan
these genes [32] or complete exomes or genomes.
While we and others have documented that the major








Costa et al. [33] 9 9 2 1 Largest indel
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Kluska et al. [59] 20 15 7 3 8 in BRCA1 (3
Yeo et al. [60] 3 3 2 0 Used multiple
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Chan et al. [61] 3 2 1 Compares So
Bosdet et al. [62] 517 18 5 4 Known varian
Total 101 54 38
All known publications using Ion Torrent sequencing instruments to sequence know
deletion variants (indels), those of 1 base pair (1bp) and those in homopolymer reg
9identifying single nucleotide variants, they can be deficient
in the prediction of insertion and deletion variants, espe-
cially in mononucleotide repeats [41]. The BRCA1 and
BRCA2 genes have numerous mononucleotide repeat re-
gions, and these areas are rich in known mutations. Thus,
a method to increase accuracy of sequencing in repeats
would be welcome. We documented that the Hi-Q en-
zyme can achieve a significantly higher accuracy in se-
quencing through mononucleotide repeats. When
combined with methods or specific assays for the most
prevalent large deletions, a high percentage of germ-
line mutations can be identified. A recent study with
the same BRCA1/2 panel was tested in a diagnostics
laboratory with high accuracy [47].and BRCA2 indels
nclusions
is a 3bp homopolymer
3 in BRCA2, established 130X as minimum coverage to detect all variants
inimum coverage of 70X to detect all variants
1bp) and 7 in BRCA2 (4 1bp)
mappers and variant callers to show that high sensitivity and specificity
ed in BRCA1/2 with Ion Torrent sequencing, but no mutations are in
rs
lidation samples and 95 unknown samples
lid to PGM, estimates reagent cost as $123 (Solid) and $220 (PGM)
ts includes SNPs. Establish 100X minimum coverage to find all variants
n BRCA1 and BRCA2 mutations are displayed. The number of insertion/
ions (homopol.) are tabulated
Dean et al. GigaScience  (2015) 4:50 In summary, we have succeeded in recruiting and
anonymously testing diverse groups of Latin American
women with breast cancer in the US, all at a materials cost
of less than $100 for samples collection, shipment and
sequencing, and confirmation. Using DNA sequencing, we
found almost exclusively rare mutations, most of which
have been observed in other studies. Expansion of this
approach could be a component of a larger effort to im-
prove the application of the benefits of genetic testing to
Hispanic American women.
Potential implications
The benefits of BRCA1 and BRCA2 testing for women
with breast and/or ovarian cancers, women with a family
history and/or elevated risk, or even all women, are evi-
dent [48]. A range of options for women at risk is cur-
rently available, including increased and more effective
screening, risk reduction through hormone reduction
therapy, and surgical intervention. As cancers in BRCA1
and BRCA2 mutation carrier subjects occur at an earlier
age, identification, education and implementation of risk
reduction has a high cost-to-benefit ratio in favor of
benefit. By reducing the cost of testing, simplifying
sample collection, and working with organizations and
clinics focusing on Hispanic communities, we address
some of the barriers to utilizing this technology. Ex-
tending this approach to larger populations, employing
counseling and analysis in approved clinical genetics
laboratories, could contribute to reducing the higher
mortality from these cancers in minority populations.
Methods
Study design and patients
Hispanic patients with breast cancer were recruited
through community organizations, dedicated clinics, public
events (Avon Walk) and through online contacts. The
study was approved by the National Cancer Institute (NCI)
Institutional Review Board (IRB) as well as the IRBs of
Texas Tech Health Science Center Hospitals at Lubbock
and El Paso, and included a confidentiality agreement from
the National Institutes for Health (NIH) [36]. Subjects were
newly diagnosed or previously treated, and gave consent in
both English and Spanish, with the protocol and question-
naire available in both languages. A validated questionnaire
was used to capture data on reproductive health, educa-
tion, income, and family history, and a pathology report
was collected to capture data on pathology and estrogen,
progesterone receptor status, as well as HER2 status.
DNA collection and extraction
Saliva (~5 ml) was collected in Oragene collection devices
(DNA-Genotek, Ontario, Canada), stored at room
temperature, and shipped at ambient temperature through
the US mail. A 0.5 ml aliquot was extracted according to10manufacturer’s instructions and quantified by a NanoDrop
(ND-1000) spectrophotometer (Thermo-Fisher, Wilmington,
DE). Per the IRB protocol, DNA samples and selected clin-
ical data were given new numbers unlinked to patient
identifiers.
DNA sequencing
Starting with 30 ng of genomic DNA, samples were proc-
essed according to the standard protocol for Ampliseq tar-
get amplification and library preparation using the targeted,
multiplex Ion AmpliSeq BRCA1 and BRCA2 Community
Panel. The panel contains 167 amplicons, covers 16.3 kb
and provides 98–100 % coverage of the coding regions of
the BRCA1 and BRCA2 genes [49]. The libraries were pre-
pared following the manufacturer’s Ion AmpliSeq Library
Preparation protocol (Life Technologies, Carlsbad, CA,
USA) and individual samples were barcoded, pooled to-
gether for the template emulsion preparation, and then se-
quenced on a P1 chip and Ion Torrent PGM Sequencer
(Thermo Fisher Scientific). Each run produced over 10 Gb
of sequence data, and each sample had an average depth of
coverage surpassing 500X. Raw sequencing reads generated
by the Ion Torrent sequencer were quality and adapter-
trimmed by Ion Torrent Suite, then aligned to the hg19 ref-
erence sequence by TMAP [50] using default parameters
(parameter file provided). Resulting BAM files were merged
according to sample names and processed through an in-
house quality control (QC) and coverage analysis pipeline,
which generated coverage summary plots and per sample
per amplicon read count heatmaps (heatmaps provided).
Aligned BAM files were left-aligned using the GATK Lef-
tAlignIndels module. Amplicon primers were trimmed
from aligned reads. Variant calls and filtering was made by
Torrent Variant Caller 4.0 (TSVC). Two slightly difference
parameter settings were used for standard sequencing en-
zyme and Hi-Q enzyme. In the Hi-Q enzyme parameter
set, variant recalibration was enabled. All other parameters,
such as minimum coverage, minimum alternative allele fre-
quency, and strand bias were the same between the two set-
tings (parameter files provided). Filtered variants were
annotated by the Glu Genetics annotation pipeline [51].
Sequence analysis
Predicted variants were manually reviewed in IGV [51]
and manually confirmed variants examined for data in
the Breast Cancer Information Core (BIC) [38], and the
ClinVar database [52]. Further analysis of variants was
performed using the Leiden Open Variation Database
(LOVD) and ALIGN-GVGD [34, 39, 54, 55]. Selected
sites for common mutations were manually examined
across all samples to ensure that the false positive rate
was low, and no additional variants detected. Selected
mutations were repeated by Sanger sequencing and gave
identical results to the PGM sequence. The newly
Dean et al. GigaScience  (2015) 4:50 described mutation, BRCA2 6005delT has been submit-
ted to LOVD (Variant ID 0000058963).
Data analysis
Data was compiled in a relational database (Filemaker)
and statistical analysis performed in STATA (StataCorp
LP, College Station, TX, USA).
Availability of supporting data
Supporting data including BAM files of standard and Hi-Q
enzyme libraries and ABI Trace files of validated mutations
are available from the GigaScience GigaDB [56]. The newly
described BRCA2 6005delT mutation has been submitted
to LOVD (Variant ID 0000058963).
Additional file
Additional file 1: Table S1. Mutation details for variants in Table 5.
(DOCX 27 kb)
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